A white blood cell engineered in a laboratory dish is giving patients with end-stage liver disease a shot at life without transplant. After four years of clinical follow-up, 70% of advanced cirrhosis patients treated with macrophage cell therapy at the University of Edinburgh remained transplant-free, compared with just 40% of those receiving standard care—a difference that could reshape how doctors approach one of medicine's cruelest diagnoses.
Cirrhosis, the severe scarring of the liver that comes at the bitter end of years of disease, kills more than 11,000 people annually in the UK alone. More devastatingly, over three-quarters of people aren't diagnosed until their liver is already beyond the point where conventional treatments work. Liver transplantation remains the only true cure, but donor organs are scarce, expensive, and simply unsuitable for many patients. People wait on transplant lists and run out of time. This new therapy, developed over more than a decade by Professor Stuart Forbes and his team at Edinburgh's Institute for Regeneration and Repair, offers something genuinely different: a chance to heal damaged tissue from the inside.
The treatment is elegant in its logic. Scientists extract immune cells called macrophages from each patient's own blood and cultivate them in the laboratory. These cells are nature's cleanup crew—white blood cells that devour infected and damaged tissue. When reinjected into the liver, they travel directly to where they're needed most, breaking down scar tissue, dampening harmful inflammation, and coaxing healthy liver cells to regenerate. The liver, uniquely among organs, possesses an almost miraculous capacity to repair itself; this therapy wakes that ability up.
The MATCH clinical trial tested the approach in 26 patients receiving macrophage therapy against 24 receiving standard medical care. The numbers tell a striking story. Eight deaths occurred among the treated group, with zero requiring transplantation. In the control group, nine patients died and five needed transplants. More than four years of follow-up data showed no serious side effects in those who received the cell therapy—a critical finding that speaks to safety as much as efficacy.
"Liver disease is a major cause of death of people in their working age," Professor Forbes noted, underscoring the stakes. "Although we can use liver transplantation as a rescue treatment for a proportion of people who have advanced liver disease, this is restricted by a lack of suitable donor organs." The human toll of this scarcity is invisible but immense: patients die waiting.
The work has already moved beyond the University of Edinburgh's labs. In 2020, Forbes co-founded Resolution Therapeutics with support from Edinburgh Innovations, the university's commercialization service. The company is now testing a refined version of the therapy, called RTX001, through a larger clinical trial called EMERALD. This next chapter reflects cautious optimism tempered by scientific rigor—the approach that transforms promising laboratory results into treatments that actually reach patients.
Published in Cell Stem Cell, the research represents collaboration across Scottish institutions: the University of Dundee, the Scottish National Blood Transfusion Service, Tayside Clinical Research Centre, and Glasgow Royal Infirmary. It also represents something subtler: the possibility that for some diseases, the cure might not require waiting for a donor, but rather asking the body to heal itself.